Overview

SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF

Status:
NOT_YET_RECRUITING
Trial end date:
2026-03-30
Target enrollment:
Participant gender:
Summary
The purpose of the current investigation is to demonstrate the efficacy of high-dose furosemide plus small-volume hypertonic saline solution and a Sodium-Glucose cotransporter-2 (SGLT-2) inhibitor among patients admitted for acute exacerbation of heart failure, in determining a significant increase in diuresis and natriuresis. It is also accompanied by a rapid reduction in body weight and a substantial decrease in hospitalization length without compromising renal function.
Phase:
PHASE4
Details
Lead Sponsor:
University of Palermo
Treatments:
dapagliflozin
Furosemide
Saline Solution, Hypertonic
Sodium-Glucose Transporter 2 Inhibitors